ProCE Banner Activity

Impact of Neratinib on CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer: Analysis of Data From Phase II/III Trials

Slideset Download
Conference Coverage
In patients with HER2+ breast cancer and CNS metastases, use of neratinib-based therapy showed CNS activity in this combined analysis of 3 clinical trials.

Released: December 20, 2019

Expiration: December 18, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen